Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Review

Radiotherapeutic alternatives for previously irradiated recurrent gliomas

Authors: Stephanie E Combs, Jürgen Debus, Daniela Schulz-Ertner

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Re-irradiation for recurrent gliomas has been discussed controversially in the past. This was mainly due to only marginal palliation while being associated with a high risk for side effects using conventional radiotherapy.
With modern high-precision radiotherapy re-irradiation has become a more wide-spread, effective and well-tolerated treatment option. Besides external beam radiotherapy, a number of invasive and/or intraoperative radiation techniques have been evaluated in patients with recurrent gliomas.
The present article is a review on the available methods in radiation oncology and summarizes results with respect to outcome and side effects in comparison to clinical results after neurosurgical resection or different chemotherapeutic approaches.
Appendix
Available only for authorised users
Literature
1.
Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, Gutin PH, Larson DA: Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys. 1996, 36: 433-441. 10.1016/S0360-3016(96)00315-X.CrossRefPubMed
2.
Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, Van Glabbeke M: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996, 36: 549-556. 10.1016/S0360-3016(96)00352-5.CrossRefPubMed
3.
Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002, 20: 2267-2276. 10.1200/JCO.2002.09.126.CrossRefPubMed
4.
Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056/NEJMoa043330.CrossRefPubMed
5.
Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, Wannenmacher MM, Debus J: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol. 2005, 181: 372-377. 10.1007/s00066-005-1359-x.CrossRefPubMed
6.
Young B, Oldfield EH, Markesbery WR, Haack D, Tibbs PA, McCombs P, Chin HW, Maruyama Y, Meacham WF: Reoperation for glioblastoma. J Neurosurg. 1981, 55: 917-921.CrossRefPubMed
7.
Dirks P, Bernstein M, Muller PJ, Tucker WS: The value of reoperation for recurrent glioblastoma. Can J Surg. 1993, 36: 271-275.PubMed
8.
Harsh GR, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987, 21: 615-621. 10.1097/00006123-198711000-00002.CrossRefPubMed
9.
Ammirati M, Galicich JH, Arbit E, Liao Y: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987, 21: 607-614.CrossRefPubMed
10.
Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol. 2002, 3: 509-524. 10.1007/s11864-002-0070-8.CrossRefPubMed
11.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999, 17: 2572-2578.PubMed
12.
Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997, 40: 484-488. 10.1007/s002800050691.CrossRefPubMed
13.
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997, 23: 35-61. 10.1016/S0305-7372(97)90019-0.CrossRefPubMed
14.
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999, 17: 2762-2771.PubMed
15.
Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M: One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004, 62: 2113-2115.CrossRefPubMed
16.
Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M: One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol 25, No 18S (June 20 Supplement), 2007: 2032. 2007
17.
Dritschilo A, Bruckman JE, Cassady JR, Belli JA: Tolerance of brain to multiple courses of radiation therapy. I. Clinical experiences. Br J Radiol. 1981, 54: 782-786.CrossRefPubMed
18.
Nordman E, Holsti LR: Roentgen and telecobalt therapy of tumors of the brain. Radiol Clin Biol. 1973, 42: 199-211.PubMed
19.
20.
Veninga T, Langendijk HA, Slotman BJ, Rutten EH, van der Kogel AJ, Prick MJ, Keyser A, van der Maazen RW: Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol. 2001, 59: 127-137. 10.1016/S0167-8140(01)00299-7.CrossRefPubMed
21.
22.
Leksell DG: Stereotactic radiosurgery. Present status and future trends. Neurol Res. 1987, 9: 60-68.PubMed
23.
Leksell L: The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951, 102: 316-319.PubMed
24.
Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. Int J Radiat Oncol Biol Phys. 2006, 64: 1341-1347. 10.1016/j.ijrobp.2005.10.024.CrossRefPubMed
25.
Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol. 2004, 180: 590-596. 10.1007/s00066-004-1299-x.CrossRefPubMed
26.
Loeffler JS, Shrieve DC, Alexander E: Radiosurgery for glioblastoma multiforme: the importance of selection criteria. Int J Radiat Oncol Biol Phys. 1994, 30: 731-733.CrossRefPubMed
27.
Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D: Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005, 104: 2168-2173. 10.1002/cncr.21429.CrossRefPubMed
28.
Herfarth KK, Izwekowa O, Thilmann C, Pirzkall A, Delorme S, Hofmann U, Schadendorf D, Zierhut D, Wannenmacher M, Debus J: Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther Onkol. 2003, 179: 366-371.CrossRefPubMed
29.
Shrieve DC, Alexander E, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler JS: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995, 36: 275-282. 10.1097/00006123-199502000-00006.CrossRefPubMed
30.
Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol. 1995, 13: 1642-1648.PubMed
31.
Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999, 45: 1133-1141. 10.1016/S0360-3016(99)00336-3.CrossRefPubMed
32.
Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005, 23: 8863-8869. 10.1200/JCO.2005.03.4157.CrossRefPubMed
33.
Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ: A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999, 43: 293-298. 10.1016/S0360-3016(98)00416-7.CrossRefPubMed
34.
Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997, 37: 393-398. 10.1016/S0360-3016(96)00455-5.CrossRefPubMed
35.
Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005, 5: 55-10.1186/1471-2407-5-55.CrossRefPubMedPubMedCentral
36.
Kjellberg RN, Hanamura T, Davis KR, Lyons SL, Adams RD: Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N Engl J Med. 1983, 309: 269-274.CrossRefPubMed
37.
Flickinger JC, Schell MC, Larson DA: Estimation of complications for linear accelerator radiosurgery with the integrated logistic formula. Int J Radiat Oncol Biol Phys. 1990, 19: 143-148.CrossRefPubMed
38.
Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer. 2005, 104: 2457-2465. 10.1002/cncr.21448.CrossRefPubMed
39.
Munter MW, Thilmann C, Hof H, Didinger B, Rhein B, Nill S, Schlegel W, Wannenmacher M, Debus J: Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol. 2003, 66: 313-321. 10.1016/S0167-8140(03)00021-5.CrossRefPubMed
40.
Munter MW, Nill S, Thilmann C, Hof H, Hoss A, Haring P, Partridge M, Manegold C, Wannenmacher M, Debus J: Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results. Strahlenther Onkol. 2003, 179: 535-541. 10.1007/s00066-003-1055-7.CrossRefPubMed
41.
Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA: Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006, 64: 892-897. 10.1016/j.ijrobp.2005.05.067.CrossRefPubMed
42.
Thilmann C, Zabel A, Grosser KH, Hoess A, Wannenmacher M, Debus J: Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumor volume in the treatment of high-grade gliomas. Int J Cancer. 2001, 96: 341-349. 10.1002/ijc.1042.CrossRefPubMed
43.
Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002, 25: 606-611. 10.1097/00000421-200212000-00017.CrossRefPubMed
44.
Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, Weaver KA, Malec M, Acord P, Lamborn KR, .: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys. 1992, 24: 583-591.CrossRefPubMed
45.
Gutin PH, Phillips TL, Wara WM, Leibel SA, Hosobuchi Y, Levin VA, Weaver KA, Lamb S: Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg. 1984, 60: 61-68.CrossRefPubMed
46.
Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, Pintilie M, Bernstein M: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998, 41: 1005-1011. 10.1016/S0360-3016(98)00159-X.CrossRefPubMed
47.
Leibel SA, Gutin PH, Wara WM, Silver PS, Larson DA, Edwards MS, Lamb SA, Ham B, Weaver KA, Barnett C: Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 1989, 17: 1129-1139.CrossRefPubMed
48.
Wen PY, Alexander E, Black PM, Fine HA, Riese N, Levin JM, Coleman CN, Loeffler JS: Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994, 73: 3029-3036. 10.1002/1097-0142(19940615)73:12<3029::AID-CNCR2820731222>3.0.CO;2-4.CrossRefPubMed
49.
Prados MD, Gutin PH, Phillips TL, Wara WM, Sneed PK, Larson DA, Lamb SA, Ham B, Malec MK, Wilson CB: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys. 1992, 24: 593-597.CrossRefPubMed
50.
Ling CC, Anderson LL, Shipley WU: Dose inhomogeneity in interstitial implants using 125I seeds. Int J Radiat Oncol Biol Phys. 1979, 5: 419-425.CrossRefPubMed
51.
Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Malkin MG, Mealey JJ, Neal JH, Olson J, Robertson JT, Barnett GH, Bloomfield S, Albright R, Hochberg FH, Hiesiger E, Green S: The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002, 51: 343-355. 10.1097/00006123-200208000-00009.PubMed
52.
Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro -oncol. 2004, 6: 119-126. 10.1215/S1152851703000425.CrossRefPubMedPubMedCentral
53.
Patel S, Breneman JC, Warnick RE, Albright RE, Tobler WD, van Loveren HR, Tew JM: Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery. 2000, 46: 1123-1128. 10.1097/00006123-200005000-00019.CrossRefPubMed
54.
Gaspar LE, Zamorano LJ, Shamsa F, Fontanesi J, Ezzell GE, Yakar DA: Permanent 125iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 1999, 43: 977-982. 10.1016/S0360-3016(98)00494-5.CrossRefPubMed
55.
Sneed PK, McDermott MW, Gutin PH: Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol. 1997, 13: 157-166. 10.1002/(SICI)1098-2388(199705/06)13:3<157::AID-SSU2>3.0.CO;2-6.CrossRefPubMed
56.
Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys. 2005, 62: 1133-1139. 10.1016/j.ijrobp.2004.12.032.CrossRefPubMed
57.
Gutin PH, Leibel SA, Wara WM, Choucair A, Levin VA, Philips TL, Silver P, Da S, Edwards MS, Davis RL, .: Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg. 1987, 67: 864-873.CrossRefPubMed
58.
Simon JM, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C, Valery CA, Delattre JY, Dormont D, Baillet F, Mazeron JJ: Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys. 2002, 53: 67-74. 10.1016/S0360-3016(01)02804-8.CrossRefPubMed
59.
Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA: An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg. 2003, 99: 297-303.CrossRefPubMed
60.
Shrieve DC, Loeffler JS: Advances in radiation therapy for brain tumors. Neurol Clin. 1995, 13: 773-793.PubMed
61.
Gabayan AJ, Green SB, Sanan A, Jenrette J, Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, Bastin KT, Watson G, Burri S, Stea B: GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006, 58: 701-709. 10.1227/01.NEU.0000194836.07848.69.CrossRefPubMed
62.
Krempien R, Roeder F, Oertel S, Weitz J, Hensley FW, Timke C, Funk A, Lindel K, Harms W, Buchler MW, Debus J, Treiber M: Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 2006, 65: 773-779.CrossRefPubMed
63.
Krempien R, Roeder F, Oertel S, Roebel M, Weitz J, Hensley FW, Timke C, Funk A, Bischof M, Zabel-Du BA, Niethammer AG, Eble MJ, Buchler MW, Treiber M, Debus J: Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006, 66: 1143-1151.CrossRefPubMed
64.
Matsutani M, Nakamura O, Nagashima T, Asai A, Fujimaki T, Tanaka H, Nakamura M, Ueki K, Tanaka Y, Matsuda T: Intra-operative radiation therapy for malignant brain tumors: rationale, method, and treatment results of cerebral glioblastomas. Acta Neurochir (Wien). 1994, 131: 80-90. 10.1007/BF01401457.CrossRef
65.
Sakai N, Yamada H, Andoh T, Takada M, Hirata T, Funakoshi T, Doi H, Yanagawa S: [Intraoperative radiation therapy for malignant glioma]. Neurol Med Chir (Tokyo). 1989, 29: 312-318.CrossRef
66.
Matsutani M, Nakamura O: [Advances of surgery and radiation therapy of glioblastoma and metastatic tumor]. Gan To Kagaku Ryoho. 1991, 18: 174-179.PubMed
67.
Schueller P, Micke O, Palkovic S, Schroeder J, Moustakis C, Bruns F, Schuck A, Wassmann H, Willich N: 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas. Strahlenther Onkol. 2005, 181: 500-506. 10.1007/s00066-005-1354-2.CrossRefPubMed
68.
Nemoto K, Ogawa Y, Matsushita H, Takeda K, Takai Y, Yamada S, Kumabe T: Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas. BMC Cancer. 2002, 2: 1-10.1186/1471-2407-2-1.CrossRefPubMedPubMedCentral
69.
Hara A, Nishimura Y, Sakai N, Yamada H, Yanagawa S: Effectiveness of intraoperative radiation therapy for recurrent supratentorial low grade glioma. J Neurooncol. 1995, 25: 239-243. 10.1007/BF01053157.CrossRefPubMed
70.
Shibamoto Y, Yamashita J, Takahashi M, Abe M: Intraoperative radiation therapy for brain tumors with emphasis on retreatment for recurrence following full-dose external beam irradiation. Am J Clin Oncol. 1994, 17: 396-399. 10.1097/00000421-199410000-00008.CrossRefPubMed
71.
Ortiz U, Santos M, Garcia-Berrocal I, Bustos JC, Samblas J, Gutierrez-Diaz JA, Delgado JM, Donckaster G, Calvo FA: Intraoperative radiation therapy in malignant glioma: early clinical results. Neurol Res. 1995, 17: 289-294.
72.
Wurm RE, Kuczer DA, Schlenger L, Matnjani G, Scheffler D, Cosgrove VP, Ahlswede J, Woiciechowsky C, Budach V: Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2006, 66: S26-S32.CrossRef
73.
Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol. 1997, 20: 226-229. 10.1097/00000421-199706000-00002.CrossRefPubMed
74.
Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000, 23: 155-159. 10.1097/00000421-200004000-00010.CrossRefPubMed
75.
Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo MG: Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999, 43: 789-793. 10.1016/S0360-3016(98)00457-X.CrossRefPubMed
76.
Chamberlain MC, Barba D, Kormanik P, Berson AM, Saunders WM, Shea MC: Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch Neurol. 1995, 52: 162-167.CrossRefPubMed
77.
Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM: Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002, 3: 487-497. 10.1016/S1470-2045(02)00818-5.CrossRefPubMed
78.
Wust P, Rau B, Gellerman J, Pegios W, Loffel J, Riess H, Felix R, Schlag PM: Radiochemotherapy and hyperthermia in the treatment of rectal cancer. Recent Results Cancer Res. 1998, 146: 175-191.CrossRefPubMed
79.
Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH: Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1998, 40: 287-295. 10.1016/S0360-3016(97)00731-1.CrossRefPubMed
80.
Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Kraft G, Wannenmacher M, Debus J: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004, 58: 631-640. 10.1016/j.ijrobp.2003.09.041.CrossRefPubMed
81.
Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, Jakel O, Karger CP, Debus J: Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005, 104: 338-344. 10.1002/cncr.21158.CrossRefPubMed
82.
J Mizoe, H Tsujii, A Hasegawa, R Takagi, T Yanagi, K Takakura: Carbon ion radiotherapy for malignant gliomas. Sixth Meeting of the European Association for NeuroOncolgy, Edinburgh, UK, 05-08 May, 2005. 2005, Abstract #421.:
83.
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991, 21: 109-122.CrossRefPubMed
Metadata
Title
Radiotherapeutic alternatives for previously irradiated recurrent gliomas
Authors
Stephanie E Combs
Jürgen Debus
Daniela Schulz-Ertner
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-167

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study

Research article

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

Study protocol

Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation study

Research article

The association of cancer survival with four socioeconomic indicators: a longitudinal study of the older population of England and Wales 1981–2000

Research article

Functional overload attenuates plantaris atrophy in tumor-bearing rats

Research article

Influence of IFN-gamma and its receptors in human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits